• Organogenesis Holdings Inc ORGO.OQ ORGO.O is expected to show a fall in quarterly revenue when it reports results on May 8 for the period ending March 31 2025

• The Canton Massachusetts-based company is expected to report a 17.5% decrease in revenue to $90.767 million from $109.98 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.The company's guidance on February 27 2025, for the period ended March 31, was for revenue between $85.00 million and $95.00 million.

• ​LSEG's mean analyst estimate for Organogenesis Holdings Inc is for a loss of 6 cents per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Organogenesis Holdings Inc is $6.00​, above​ its last closing price of $5.20. ​​​

The company's guidance on February 27 2025 for the period ended March 31 was for gross profit margin between USD76% and USD78%.

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated May 6 at 23:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)